ReviewFrontiers in oncology2026
Progress in molecular markers associated with radiotherapy efficacy in glioma.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alpha particle therapy in glioblastoma: emerging biomarkers, mechanisms of response, and translational opportunities.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy remains a cornerstone in glioma treatment, yet its efficacy is significantly hindered by tumor heterogeneity and molecularly driven radioresistance. This review systematically delineates molecular biomarkers that influence radiotherapy outcomes, categorizing them into radiosensitivity (e.g., IDH1 mutations, MGMT promoter methylation, TIM-3) and radioresistance (e.g., CD133, CD44, PRMT1, CSF-1R,RAD51,HMGB2). Mechanistically, radiosensitivity is governed by DNA repair fidelity (MGMT), ferroptosis suppression (PRMT1), and immune modulation (TIM-3/TAMs). Radioresistance arises from cancer stem cell maintenance (CD133/HMGB2), TAM polarization (CSF-1R/CD44), and enhanced homologous recombination (RAD51). Integrating molecular stratification into radiotherapy paradigms demonstrates clinical utility: MGMT methylation permits radiation dose de-escalation (52-54 Gy vs. 60 Gy) without compromising survival (32 vs. 25 months), while TIM-3 expression predicts responsiveness to combinatorial immunotherapy. A multi-omics AI model combining radiomics, dosiomics, and clinical data to predict radiotherapy response in glioma. Using a support vector machine trained on 176 patients, the fused model achieved an AUC of 0.728(95% CI:0.717-0.739) in validation, outperforming single-modality approaches. These advances underscore the transformative potential of biomarker-guided precision radiotherapy, enabling tailored interventions that counteract resistance mechanisms and synergize with immunotherapies. By bridging molecular insights with clinical innovation, this paradigm shift promises to redefine glioma management, offering renewed hope for overcoming therapeutic recalcitrance in this devastating malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.